Intracranial Arterial Aneurysm
Conditions
Keywords
Intracranial Arterial Aneurysm, Surpass Evolve Flow Diverter
Brief summary
Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms
Detailed description
This study aims to retrospectively evaluate the efficacy and safety of the Surpass Evolve Flow Diverter in treating complex intracranial aneurysms. It seeks to assess long-term outcomes and complication rates while analyzing the impact of patient characteristics and aneurysm types on treatment effectiveness. By collecting data from multiple centers, the study ensures broad representativeness, ultimately providing valuable insights for clinical management on a global scale.
Interventions
DEVICEFlow diverting
Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.
Sponsors
Yibin Fang
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years with a confirmed diagnosis of intracranial aneurysm. 2. Imaging studies confirming suitability for Surpass Evolve Flow Diverter treatment. 3. Aneurysms meeting flow diverter treatment indications (e.g., aneurysms larger than 4 mm). 4. At least six months of follow-up data available post-treatment.
Exclusion criteria
1. Patients with acutely ruptured aneurysms or significant bleeding. 2. Patients with incomplete data or insufficient follow-up records.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete aneurysm occlusion rate | 12(-3 ~ +6) months | — |
| Favorable prognosis rate | 12(-3 ~ +6) months | mRS score 0-1 |
| Procedure-related complication rate | 12(-3 ~ +6) months | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of postoperative stroke/TIA | 12(-3 ~ +6) months |
| Procedural success rate | 12(-3 ~ +6) months |
| Rates of postoperative intracranial hemorrhage and neurological deficits | 12(-3 ~ +6) months |
| Perioperative complication rate | 12(-3 ~ +6) months |
| Neurological mortality rate | 12(-3 ~ +6) months |
Countries
China
Outcome results
None listed